HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS UNDERGOING TRANS-ARTERIAL CHEMO-EMBOLIZATION FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA

Nauman Al-Qamari, Amjad Sattar, Hatem Adel

Abstract


OBJECTIVE

To determine the health related quality of life in patients undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma

METHODS

A before and after survey was conducted from February 2014 till December 2015 and all patients who underwent TACE irrespective of age and gender with at least one follow up at or after 06 weeks were included. Patients who lost to follow up were excluded. Short form 12 questionnaire was used to assess health-related quality of life before and after TACE. These information along with demographic of the patients like age, gender, duration of follow-up, bilirubin level, tumor size and child score was calculated.

RESULTS

Out of total 53 patients, female preponderance was found to be higher 42 (79.2%) than that of males 11 (20.8%). Majority of the patients were had hepatitis C 47 (88.7%) whereas hepatitis B infection was found in 6 (11.3%) patients. Majority of the patients were presented with child score B 34 (64.2%) followed by child score A 17 (32.1%) whereas only 2 (3.8%) patients were presented with child score C. Significant difference was observed in the physical and mental quality of life before and after TACE, i.e. 45.3 (42.2-47) vs. 46.2 (44.2-47.2), p-value <0.001 and 52.3 (48.9-54) vs. 56.3 (53.4-58.9), p-value <0.001 respectively.

CONCLUSION

Significant improvement in physical and mental health related quality of life was observed in patients suffering from hepatocellular carcinoma undergoing TACE.

Full Text:

PDF

References


REFERENCES:

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001;94:153–156.

Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC gastroenterology. 2012;12(1):64.

Munaf A, Memon MS, Kumar P, Ahmed S, Kumar MB. Comparison of Viral Hepatitis-Associated Hepatocellular Carcinoma Due to HBV and HCV-Cohort from Liver Clinics in Pakistan. Asian Pacific journal of cancer prevention: APJCP. 2014;15(18):7563.

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.

El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.

Omata M, Lesmana LA, Tateishi R. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.

Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol. 2000;7:593–600.

Llovet JM, Real MI, Montaña X. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

Koh PS, Chan AC, Cheung TT, Chok KS, Dai WC, Poon RT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB. 2015 Oct 1.

Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D et al. 2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.Ann Oncol. 2009;20 (Suppl. 7):vii1–vii6

Kato T, Nemoto R, Mori H, Takahashi M, Tamakawa Y, Harada M. Arterial chemoembolization with microencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects. JAMA. 1981;245:1123-7.

Okuda S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues (editorial). Hepatology 1998;27:1743-4.

Shun SC, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. The oncologist. 2012;17(5):732-9.

Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. Journal of Vascular and Interventional Radiology. 2010;21(7):1024-30.

Eltawil KM, Berry R, Abdolell M, Molinari M. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. HPB. 2012;14(5):341-50.

Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB et al. Treatment of unresectable cholangiocarcinoma with gemcitabine based transcatheter arterial chemoembolization (TACE): a single institution experience. J Gastrointest Surg. 2008;12:129–37.

Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology. 2004;13:73–79.

Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res. 2007;16:389–97.

Maly RC, Umezawa Y, Ratliff CT, Leake B. Racial/ethnic group differences in treatment decision-making and treatment received among older breast carcinoma patients. Cancer. 2006;106:957–65.

Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP. Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer. 2009;17:117–27.

Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, Kirstein MM, Marquardt S, Rodt T. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. CardioVascular and Interventional Radiology. 2017:1-8.


Refbacks

  • There are currently no refbacks.


© Copyright PJR 2008-